New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
All of the free stories from today.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | all day >>
07:25 EDTVTNRVertex Energy initiated with a Buy at Stifel
Subscribe for More Information
07:25 EDTLANCLancaster Colony reports Q4 EPS cont ops 76c, consensus 99c
Subscribe for More Information
07:25 EDTECOLUS Ecology initiated with a Buy at Stifel
Target $52.
07:24 EDTHCCIHeritage-Crystal Clean initiated with a Hold at Stifel
Subscribe for More Information
07:24 EDTTGTTarget margins likely to remain under significant pressure, says MKM Partners
Subscribe for More Information
07:23 EDTSPLSStaples reiterated as an Underperform at BofA/Merrill
BofA/Merrill reiterated its Underperform rating on Staples following soft Q2 results and guidance. The firm lowered estimates and does not see an inflection point in sight. Price target is $9.
07:20 EDTLOWLowe's to continue to benefit from favorable trends, says BofA/Merrill
Subscribe for More Information
07:19 EDTFutures higher as market looks to extend rally
Subscribe for More Information
07:18 EDTTIVOTiVo volatility elevated into Q2 and outlook
TiVo September call option implied volatility is at 35, October is at 29, November is at 28; compared to its 26-week average of 31 according to Track Data, suggesting large near term price movement into the expected release of Q2 after the market close on August 26.
07:18 EDTNAV, PCAR, CMI, ALSN, ETNJuly Class 8 sales rose 16% year-over-year, says JPMorgan
Subscribe for More Information
07:18 EDTTM, VLKAY, NSANY, HMC, GM, F, FIATYChina considering new anti-trust rules for auto sector, China Daily says
Subscribe for More Information
07:15 EDTGALEGalena announces resignation of CEO Mark Ahn
Galena Biopharma announced that Mark Schwartz, Ph.D., has been appointed as President and CEO, effective immediately. Dr. Schwartz was previously Galena's COO. He replaces Mark Ahn, Ph.D. who has resigned as the President and CEO and as a director of the company to pursue "other long held personal and professional goals." It is expected that Dr. Schwartz will also be appointed to Galena's board.
07:14 EDTTSLTrina Solar's Duo-Max module receives certifications from UL and TUV Rheinland
Subscribe for More Information
07:13 EDTNMNavios Maritime reports Q2 adjusted EPS (9c), consensus (13c)
Subscribe for More Information
07:12 EDTLLYEli Lilly announces results from pivotal UNCOVER studies for ixekizumab
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.
07:11 EDTPLABPhototronics upgraded to Buy from Hold at Needham
Subscribe for More Information
07:11 EDTADESAdvanced Emissions provides update on accounting review
Advanced Emissions announced that the Audit Committee of its board, upon the recommendation of the company's management, has determined that the company's financial statements filed on Form 10-Q for the quarters ended March 31, June 30, and September 30 of 2011 and 2012, or the annual financial statements filed on Form 10-K for the years ended December 31, 2011 and 2012 should not be relied upon and will likely be restated. The re-audits are still in progress, but based upon adjustments that have been identified to date, which impact a significant number of individual balance sheet and income statement line items, and the likelihood of additional adjustments as the re-audits continue, the company has determined it should make a non-reliance determination at this time. As part of the re-audit, the company is also evaluating whether or not the financial statements of Clean Coal Solutions, should have been consolidated or accounted for as an equity method investment in the Non-Reliance Periods. This evaluation includes additional technical accounting research, review of complex key documents, and consultation with current and former public accounting firms, and the company is still in the process of making its determination. If the company determines that it should have accounted for its investment in CCS under the equity method, this would materially impact, and require a restatement of, the company's previously reported financial statements for the Non-Reliance Periods. Whether the company accounts for CCS on a consolidated basis or as an equity investment, it does not change the company's ownership in, or the economic benefits the company receives from, CCS.
07:11 EDTCYBXCyberonics sees FY15 EPS $2.33-$2.39, consensus $2.36
Subscribe for More Information
07:11 EDTCGENCompugen reacquires Baize's financial interest in pipeline product candidates
Subscribe for More Information
07:09 EDTCYBXCyberonics reports Q2 adjusted EPS 53c, consensus 55c
Reports Q2 revenue $72M, consensus $74.05M; Reports Q2 international sales $13.2M, Q2 U.S. sales $58.8M.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use